BiotechTube

Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Allergic Rhinitis

Conditions

Seasonal Allergic Rhinitis

Trial Timeline

Jan 27, 2014 → Feb 28, 2014

NCT ID
NCT03444506

About Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray

Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray is a phase 2 stage product being developed by Glenmark Pharmaceuticals for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03444506. Target conditions include Seasonal Allergic Rhinitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03444506Phase 2Completed

Competing Products

20 competing products in Seasonal Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
Bilastine + Desloratadine + PlaceboYuhanPhase 3
77
ASP4070 + PlaceboAstellas PharmaPhase 2
52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
52
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
77
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
52
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
33
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + PlaceboAstraZenecaPhase 2
52
budesonide + PlaceboAstraZenecaPhase 2
52
Ciclesonide + PlaceboAstraZenecaPhase 3
77
Ciclesonide Nasal SprayAstraZenecaPhase 3
77
Budesonide + Fluticasone propionate + PlaceboAstraZenecaPhase 3
77
Ciclesonide + Ciclesonide PlaceboAstraZenecaPhase 3
77
loratadineMerckPre-clinical
23
MK0524MerckPhase 2
52
loratadine; montelukastMerckPhase 3
77

Other Products from Glenmark Pharmaceuticals

Nitric OxidePhase 3
77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerPhase 3
77
Diclofenac Sodium gel, 1% + Voltaren® Gel + PlaceboPhase 3
77
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)Phase 3
77
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboPhase 3
77